Long-term efficacy of infliximab treatment for AA-amyloidosis secondary to chronic inflammatory arthritis.
Keersmaekers
T
T
Claes
K
K
Kuypers
D R
DR
de Vlam
K
K
Verschueren
P
P
Westhovens
R
R
D000328:Adult; D000368:Aged; D000686:Amyloidosis / Q000188:drug therapy*; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D001168:Arthritis / Q000150:complications*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D000069285:Infliximab; D008297:Male; D000685:Serum Amyloid A Protein; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D000685:Serum Amyloid A Protein; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab